Form 4: RA Capital Executes Stock-to-Warrant Exchange at Prelude

RA Capital Management exchanged 1.4 million shares of Prelude Therapeutics common stock for pre-funded warrants.

Summary

• RA Capital Healthcare Fund, L.P. entered into an exchange agreement with Prelude Therapeutics on April 27, 2026.
• The Fund exchanged 1,407,000 shares of common stock for a pre-funded warrant exercisable for the same number of shares.
• The pre-funded warrant has an exercise price of $0.0001 per share.
• The transaction resulted in no change to the total beneficial ownership count, merely a shift in the form of equity held.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative transaction involving a change in the form of equity ownership by a major shareholder, with no net change in total beneficial interest.

Positives

• The transaction maintains the Fund's economic interest in the company while providing flexibility in equity structure.

Negatives

• The exchange reflects a strategic shift by a major shareholder, which may signal specific tax or regulatory management preferences.

Risks

• The warrant contains a 9.99% beneficial ownership blocker, limiting the immediate ability of the Fund to increase its stake beyond this threshold.

Future Outlook

The filing does not provide forward-looking guidance regarding company operations, focusing strictly on the change in beneficial ownership structure.

Management Comments

• The reporting persons disclaim beneficial ownership of the reported securities, except to the extent of their respective pecuniary interest therein.

Industry Context

StockSavvy.ai notes that institutional investors in the biotech sector frequently utilize pre-funded warrants to manage ownership percentages and comply with regulatory thresholds while maintaining economic exposure to the issuer.

Comparison to Industry Standards

• The use of pre-funded warrants is a standard mechanism in biotech financing to avoid immediate dilution or to manage ownership caps under Section 16 of the Exchange Act.

Related Party Transactions

• The transaction was conducted directly between the Issuer (Prelude Therapeutics) and the Fund (RA Capital Healthcare Fund, L.P.), an affiliate of the reporting persons.

Stakeholder Impact

• Shareholders should note the continued significant involvement of RA Capital, though the shift to warrants may indicate a desire to manage voting power or regulatory reporting requirements.

Next Steps

• Potential future exercise of the pre-funded warrants by RA Capital, subject to the 9.99% ownership blocker.

Key Dates

Keywords

Prelude Therapeutics, PRLD, RA Capital Management, Form 4, Insider Trading, Equity Exchange, Pre-funded Warrants